TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06221098

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bilateral medial rectus recession
Description: release muuscle from its original insertion and backword inserted in sclera

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bilateral medial rectus recession
Description: release muuscle from its original insertion and backword inserted in sclera

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bilateral medial rectus recession
Description: release muuscle from its original insertion and backword inserted in sclera
Study: NCT06465914

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine (Hansenula Polymorpha)
Description: Subjects received 3 doses of 9-valent HPV vaccine according to a 0, 2, 6-month schedule (0.5 mL intramuscular injection in the deltoid muscle).

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects received 3 doses of Placebo according to a 0, 2, 6-month schedule (0.5 mL intramuscular injection in the deltoid muscle).
Study: NCT06490172

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shock wave therapy
Description: Radial Extracorporeal Shock Wave Therapy and feasibility as treatment for adhesive capsulitis
Study: NCT06215287

Intervention type: OTHER
Intervention: Physician survey
Description: Survey to assess physicians' knowledge of Exjade posology and biological monitoring recommendations as described in the Educational Materials
Study: NCT05159986

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group that received aplication of Diadynamic currents associated to Exercise during eight weeks with three sessions a week
Description: Diadynamic currents was performed followed by exercises (divided into Phase-1, Phase-2 and Phase-3 during eight weeks with three sessions a week).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group that received exercise during eight weeks with three sessions a week
Description: The intervention was divided into Phase-1, Phase-2 and Phase-3 during eight weeks with three sessions a week. Each session lasted 45 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group that received exercise during eight weeks with three sessions a week
Description: The intervention was divided into Phase-1, Phase-2 and Phase-3 during eight weeks with three sessions a week. Each session lasted 45 minutes.
Study: NCT05260554

Intervention type: DRUG
Intervention: Fosfomycin
Description: In this group with urinary tract inflammation; Fosfomycin was prescribed for 7 days (3 doses, 2 days apart). There are 80 patients in total.

Intervention type: DIETARY_SUPPLEMENT
Intervention: Cranberry
Description: In this group with urinary tract inflammation; 7 days (used every day) cranberry tablet was given. There are 80 patients in total.
Study: NCT06511375

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sprint training
Description: sprint training involves 20 meters sprint power training involve countermovement jump, squat jump and broad jump

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Power Training
Description: GROUP 2 will perform POWER TRAINING for 4 weeks, 3 sessions per week Participants will perform Countermovement jump 2 trials, with 1-minute recovery between each trial for four weeks, three times per week.~Participants will perform squat jump 2 trials with 1-minute recovery between each trial for four weeks, three times per week.~Participants will perform broad jump 2 trials with 1-minute recovery between each trial for four weeks, three times per week.
Study: NCT05903677

Intervention type: OTHER
Intervention: magnesium levels
Description: Detection of the relationship between cardiac surgery associated AKI and preoperative magnesium levels.
Study: NCT05554042

Intervention type: DIAGNOSTIC_TEST
Intervention: Kintsugi Voice Device
Description: The Kintsugi Voice Device is an API with an underlying machine learning algorithm that drives the Device outputs. Depression and Anxiety are separate algorithms. The Device is designed to be adjunct to clinical assessment and estimate the presence of vocal characteristics consistent with a significant depressive episode and/or a clinically significant anxiety state, which are a necessary condition for the diagnosis of lifetime mood disorders, such as major depressive disorder and/or generalized anxiety disorder. Kintsugi Voice Device is not to be used in-lieu of full patient evaluation or relied upon to make or confirm diagnosis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Kintsugi Voice Device
Description: The Kintsugi Voice Device is an API with an underlying machine learning algorithm that drives the Device outputs. Depression and Anxiety are separate algorithms. The Device is designed to be adjunct to clinical assessment and estimate the presence of vocal characteristics consistent with a significant depressive episode and/or a clinically significant anxiety state, which are a necessary condition for the diagnosis of lifetime mood disorders, such as major depressive disorder and/or generalized anxiety disorder. Kintsugi Voice Device is not to be used in-lieu of full patient evaluation or relied upon to make or confirm diagnosis.
Study: NCT05490134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone
Description: A 0.15 mg/kg bolus dose of naloxone in 10ml normal saline will be administered via an intravenous (IV) line inserted into the antecubital vein of the non-dominant arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone
Description: A 0.15 mg/kg bolus dose of naloxone in 10ml normal saline will be administered via an intravenous (IV) line inserted into the antecubital vein of the non-dominant arm.
Study: NCT06478810

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Domomedicine and dedicated nursing care for a close and secure monitoring after an ambulatory hepatectomy
Description: For patient who need a minor hepatectomy under laparoscopy for the standard of care, the follow-up will be an ambulatory follow-up. This ambulatory follow-up will be made possible thanks to the integration of Domomedicine and dedicated nursing care for a close and secure monitoring.
Study: NCT06276101

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NWRD08 administered by electroporation
Description: DNA plasmid delivered via IM injection + electroporation using TERESA device
Study: NCT05784649

Intervention type: OTHER
Group type: OTHER
Intervention: health education
Description: The health education program will be conducted on the WeChat platform. The contents of health education include 1) knowledge about how to prevent anemia during pregnancy; 2) self-care education videos such as breastfeeding; 3) online courses on how to manage weight during pregnancy, and how to keep good emotions, etc.; 4) Nutrition and lifestyle guidance; 5) knowledge about recognition and prevention of risk factors or diseases: abortion, toxic substances, premature birth. The contents of health education will be totally shared 5 times from 12 weeks to 36 weeks in the pregnancy and once a month on the platform. Every participant should reply read after learning the contents. if they have any questions, they can reply for help for further connection with health professionals.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: individual counsel
Description: The participants will receive the same health education as the control group. The pregnant women will have one routine checkup a month from 12 weeks to 36 weeks in the hospital. And they will receive counseling with a midwife and a doctor after every routine checkup. The counseling will have a total of 5 times and once a month, 45 minutes per time. The professionals will evaluate health-promoting behaviors such as nutrition and physical activity based on the procedure of the health promotion model. The model includes four continued parts: prior behaviors; personal influences; interpersonal Influences; commitment to a plan of action. Finally, the professionals will give person-centered advice to help the participants practice the content of health education, keep health-promoting behaviors, and achieve a healthy lifestyle.
Study: NCT05490134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone
Description: A 0.15 mg/kg bolus dose of naloxone in 10ml normal saline will be administered via an intravenous (IV) line inserted into the antecubital vein of the non-dominant arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone
Description: A 0.15 mg/kg bolus dose of naloxone in 10ml normal saline will be administered via an intravenous (IV) line inserted into the antecubital vein of the non-dominant arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: 0.15mg/kg bolus of normal saline in 10ml normal saline will be administered via an intravenous (IV) line inserted into the antecubital vein of the non-dominant arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: 0.15mg/kg bolus of normal saline in 10ml normal saline will be administered via an intravenous (IV) line inserted into the antecubital vein of the non-dominant arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: 0.15mg/kg bolus of normal saline in 10ml normal saline will be administered via an intravenous (IV) line inserted into the antecubital vein of the non-dominant arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: 0.15mg/kg bolus of normal saline in 10ml normal saline will be administered via an intravenous (IV) line inserted into the antecubital vein of the non-dominant arm.
Study: NCT05610072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: n-acetylcysteine
Description: Subjects will be randomized to receive 2.4 oral n-acetylcysteine daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydromorphone
Description: Subjects will receive up to 192 mg oral hydromorphone daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: Subjects will receive up to 192 mg oral hydromorphone daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo n-acetylcystine
Description: Subjects will be randomized to receive placebo n-acetylcysteine daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo hydromorphone
Description: Prior to some experimental sessions, subjects will receive placebo hydromorphone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo hydromorphone
Description: Prior to some experimental sessions, subjects will receive placebo hydromorphone
Study: NCT06193148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib
Description: Participants will receive Jaktinib orally for single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib
Description: Participants will receive Jaktinib orally for single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib
Description: Participants will receive Jaktinib orally for single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib
Description: Participants will receive Jaktinib orally for single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive Placebo orally for single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive Placebo orally for single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive Placebo orally for single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive Placebo orally for single dose
Study: NCT06469697

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School music broadcast
Description: An arts-based eye health intervention featuring traditional and contemporary music pieces will be broadcasted at both school and community levels.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Community music broadcast
Description: An arts-based eye health intervention featuring traditional and contemporary music pieces will be broadcasted at community levels.
Study: NCT05320068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Vancomycin
Description: A blinded capsule that contains 125mg of vancomycin every 6 hours during 10 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A blinded capsule that contains no vancomycin every 6 hours during 10 days.
Study: NCT06027307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enavogliflozin
Description: All study patients will receive enavogliflozin in addition to their prior medications. They will receive optimal medical treatment for their underlying disease such as hypertension, diabetes, arrhythmia and/or coronary artery disease.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All study patients will receive placebo in addition to their prior medications. They will receive optimal medical treatment for their underlying disease such as hypertension, diabetes, arrhythmia and/or coronary artery disease.
Study: NCT06358430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TROP2-CAR-NK Cells
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimiducid (AP1903)
Description: Given by IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphodepleting Chemotherapy
Description: Given by Chemotherapy
Study: NCT06517173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Y-3 for injection
Description: Qualified subjects were randomly divided into groups in a 1:1 ratio and received continuous treatment with Y-3 injection (40 mg/dose, qd) or placebo control drug. The treatment was performed 10 times for 10 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control group
Description: Qualified subjects were randomly divided into groups in a 1:1 ratio and received continuous treatment with Y-3 injection (40 mg/dose, qd) or placebo control drug. The treatment was performed 10 times for 10 days.
Study: NCT04877444

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Duck Duck Punch
Description: Duck Duck Punch (DDP) is an interactive computer game deliberately designed to enhance UE movement quality via individualized progressive movement practice. DDP is unique as it uses Microsoft Kinect skeletal tracking technology to assess movement performance. The participant sits in front of the Microsoft Kinect and controls a virtual arm with his/her physical arm; reaching forward to punch virtual ducks. The goal 'dose' of DDP will be 200 repetitions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Duck Duck Punch
Description: Duck Duck Punch (DDP) is an interactive computer game deliberately designed to enhance UE movement quality via individualized progressive movement practice. DDP is unique as it uses Microsoft Kinect skeletal tracking technology to assess movement performance. The participant sits in front of the Microsoft Kinect and controls a virtual arm with his/her physical arm; reaching forward to punch virtual ducks. The goal 'dose' of DDP will be 200 repetitions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Subjects will perform 15 minutes of aerobic exercise on a recumbent stationary cycle. The target intensity of aerobic exercise is 70% heart rate reserve. Following aerobic exercise subject will play an upper extremity rehabilitation game called Duck Duck Punch.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lower extremity stretching
Description: Subjects will perform 15 minutes of lower extremity stretching. Following aerobic exercise subject will play an upper extremity rehabilitation game called Duck Duck Punch.
Study: NCT05690165

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking Exercise
Description: Heart rate controlled walking exercise
Study: NCT06644222

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: AIRROSTI exercises
Description: Group A will receive AIRROSTI exercises for 45 minutes / one session daily for five days per week

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Thera band exercises
Description: Group B will receive Thera band exercises for 45 minutes/one session per day for five days per week.
Study: NCT05993026

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental health course
Description: The student course involves classroom-based teaching of eight lessons over eight weeks. The aim is to strengthen students' faith in their own abilities (self-efficacy) and ability to understand themselves and others (mentalization). In this way, students become better at entering into positive relationships and communities as well as better at handling everyday challenges both academically and socially. The student course includes teaching, exercises and training in simple tools for mastery and mentalization. The student courses in the classes are handled by staff close to the students and are based on both physical and digital material as well as an app for the students. The employees initially participate in a competency development course.
Study: NCT06482177

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclosporine ophthalmic solution
Description: Cyclosporine BID in the study eye
Study: NCT05737017

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ClearCoajet
Description: The ClearCoajet is a new hemostasis device with a hybrid function (Coagulation + Injection) and is developed to provide effective coagulation, injection, and marking around lesions without changing devices during the endoscopic procedure.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ClearCoajet
Description: The ClearCoajet is a new hemostasis device with a hybrid function (Coagulation + Injection) and is developed to provide effective coagulation, injection, and marking around lesions without changing devices during the endoscopic procedure.
Study: NCT05524844

Intervention type: OTHER
Intervention: Sample Collection
Description: Saliva, gastric aspirate, and esophageal brushings and biopsies.

Intervention type: OTHER
Intervention: Sample Collection
Description: Saliva, gastric aspirate, and esophageal brushings and biopsies.

Intervention type: OTHER
Intervention: Endoscopy results
Description: Results from standard of care endoscopy (scheduled separate of study)

Intervention type: OTHER
Intervention: Endoscopy results
Description: Results from standard of care endoscopy (scheduled separate of study)

Intervention type: OTHER
Intervention: Dietary questionnaire
Description: Diet History Questionnaire (II)

Intervention type: OTHER
Intervention: Dietary questionnaire
Description: Diet History Questionnaire (II)
Study: NCT06390761

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: All acupoints were selected based on traditional Chinese medicine theory and previous articles on PD and constipation.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Acupuncture
Description: All acupoints were selected based on traditional Chinese medicine theory and previous articles on PD and constipation.
Study: NCT05234034

Intervention type: OTHER
Intervention: online survey
Description: participantion consists of filling in an online survey that will take approximately 53 minutes. An adapted battery of questionnaires is provided for each subgroup.

Intervention type: OTHER
Intervention: online survey
Description: participantion consists of filling in an online survey that will take approximately 53 minutes. An adapted battery of questionnaires is provided for each subgroup.

Intervention type: OTHER
Intervention: online survey
Description: participantion consists of filling in an online survey that will take approximately 53 minutes. An adapted battery of questionnaires is provided for each subgroup.

Intervention type: OTHER
Intervention: online survey
Description: participantion consists of filling in an online survey that will take approximately 53 minutes. An adapted battery of questionnaires is provided for each subgroup.

Intervention type: OTHER
Intervention: online survey
Description: participantion consists of filling in an online survey that will take approximately 53 minutes. An adapted battery of questionnaires is provided for each subgroup.

Intervention type: OTHER
Intervention: online survey
Description: participantion consists of filling in an online survey that will take approximately 53 minutes. An adapted battery of questionnaires is provided for each subgroup.
Study: NCT06254235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The test octreotide microsphere
Description: A single intramuscular dose of the test octreotide microsphere 30mg,

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: The reference octreotide microsphere
Description: A single intramuscular dose of the reference octreotide microsphere 30mg
Study: NCT06221813

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PHV02
Description: Nipah virus vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PHV02
Description: Nipah virus vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PHV02
Description: Nipah virus vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PHV02
Description: Nipah virus vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PHV02
Description: Nipah virus vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PHV02
Description: Nipah virus vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Lactated Ringer's
Description: Placebo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Lactated Ringer's
Description: Placebo
Study: NCT06044272

Intervention type: OTHER
Intervention: Factors associated
Description: Factors associated with the type of resistance by microorganisms.

Intervention type: OTHER
Intervention: Factors associated
Description: Factors associated with the type of resistance by microorganisms.

Intervention type: OTHER
Intervention: Factors associated
Description: Factors associated with the type of resistance by microorganisms.

Intervention type: OTHER
Intervention: Factors associated
Description: Factors associated with the type of resistance by microorganisms.

Intervention type: OTHER
Intervention: Factors associated
Description: Factors associated with the type of resistance by microorganisms.
Study: NCT05017025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aurora A Kinase Inhibitor LY3295668
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Given PO